Leo Cancer Care Receives FDA 510(k) Clearance for Marie® - A Revolutionary Upright Radiotherapy Platform
Marie represents a paradigm shift in the delivery of particle therapy, combining an upright patient positioning system and a CT scanner that reimagines the treatment experience for both patients and clinicians, whilst drastically reducing the size and cost compared to existing particle therapy solutions.
"This clearance marks a major milestone not just for Leo Cancer Care, but for the future of cancer treatment," said Stephen Towe, CEO of Leo Cancer Care. "We've long believed there's a better, more human way to deliver radiotherapy. One that puts the patient at the heart of the treatment experience and embraces smarter, more compassionate design. Marie is the embodiment of that belief."
Particle therapies such as proton and carbon ion therapy have long been considered the gold standard in radiation oncology. However, the cost, size, and complexity of conventional systems with large rotating gantries have historically limited widespread adoption.
Leo Cancer Care's upright solution addresses these barriers. By rotating the patient rather than the beam, Marie eliminates the need for a rotating gantry, dramatically reducing infrastructure costs, simplifying installation, and expanding access to this advanced level of care.
Marie is particle beam-agnostic, meaning it's compatible with a wide range of current and emerging treatment modalities, including proton, carbon ion, BNCT and FLASH therapies. Its upright design opens new possibilities for treatment planning and delivery, particularly for tumors in the thoracic and abdominal regions. When compared to supine treatments, evidence suggests anatomical shifts are reduced due to the gravitational direction.
Through collaborations with leading hospitals around the world, Leo Cancer Care is conducting clinical research and trials, laying a strong foundation for the widespread adoption of upright therapy as a new standard in radiotherapy.
"We are incredibly proud of the teams and collaborators who helped bring Marie to life," added Thomas 'Rock' Mackie, Co-founder and Board Chairman of Leo Cancer Care. "This is just the beginning. We're working closely with leading particle beam companies and institutions worldwide to explore how upright positioning can unlock new levels of precision and personalization in cancer care."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
5 hours ago
- Korea Herald
Breaking Through Core CT Technology Barriers!
World-Class Innovations to Debut at 2025 Medtec in September SHANGHAI, Aug. 4, 2025 /PRNewswire/ -- A quiet revolution is underway in the field of high-end medical equipment, led by China's growing innovation power. Core CT technologies, once dominated by international giants, are now being steadily unlocked by Chinese companies, breaking through long-standing technical barriers. As a key showcase of this industrial transformation, the 2025 Medtec International Medical Device Design & Manufacturing Technology Exhibition will take place from September 24 to 26 at Halls 1 & 2, Shanghai World Expo Exhibition and Convention Center. The exhibition will reach a record-breaking scale of 45,000 square meters, bringing together over 1,000 top-tier companies from nearly 27 countries and regions around the world. Among the standout participants, Shanghai Xixin Medical Technology Co., Ltd., Guangzhou Wiserscope Photoelectric Medical Technology Co., Ltd., Wuxi Innosonics Medical Technology Co., Ltd., SmartVein (Jiaxing) Medical Technology Co., Ltd., and Shanghai AIMIC Medical Electronics Co., Ltd. will make major appearances, showcasing their latest technological breakthroughs and product applications to a highly targeted audience of professional buyers. Click to Register for FREE > 01. CT X-Ray Tubes: From Industry Bottleneck to the Rise of "Domestic Cores" In the realm of high-end medical devices, CT scanners are often referred to as the "eyes of modern medicine"—their performance directly impacts image quality and equipment lifespan. At the heart of these systems, the X-ray tube and detector act as the "retina" and "lens." For years, these critical components have been dominated by global giants like GE, Siemens, and Philips. As a result, Chinese medical institutions have faced costly challenges—millions spent on consumables and equipment outages lasting over a month while waiting for repairs. Now, change is underway. In the first half of 2025, the number of registered domestic CT devices surged by 47% year-over-year. Even more significant, the localization rate of core components has crossed the 60% threshold—a historic milestone. Behind this achievement lies the power of collaborative innovation, driven by coordinated efforts among upstream and downstream enterprises across the industry chain: 02. Localization Accelerates for the "Core" of CT Systems Driven by the rapid growth of China's healthcare industry and an aging population, domestic demand for CT systems and X-ray tubes continues to surge. Today, China has become the world's largest consumer market for medical CT tubes. According to recent medical procurement data, domestic CT system sales in 2024 have caught up with those of imported brands, with Chinese manufacturers now leading the market in share. Often referred to as the "core" of the CT system, the X-ray tube is a vital component in the medical imaging supply chain—accounting for roughly 20% of a CT system's bill of materials (BOM). As a high-value consumable, CT tubes typically need replacement every two and a half years. In high-volume hospitals, that replacement cycle can shorten to just one year. From 2022 to 2024, domestic demand for medical CT tubes was 12,275, 12,317, and 12,713 units, respectively—marking a 3.57% increase in 2024 compared to 2022. As a critical high-value consumable in medical CT equipment, a single CT tube can cost up to several million yuan. Data shows that the average lifespan of a CT tube in China is just 13 months—effectively requiring replacement nearly every year. The real challenge in CT tube manufacturing lies in achieving exceptional precision and stability. Given their high cost and short service life, CT tubes have become a competitive focal point between CT system manufacturers and tube suppliers. Domestic companies such as Kunshan Medical Source, CETC, Beijing SmartBeam, and Zhuhai Rcan have secured registrations for multiple CT tube models. For local CT system manufacturers, adopting domestically produced tubes offers a key technological advantage in reducing costs and boosting overall market competitiveness. Since the 12th Five-Year Plan, China has consistently identified CT tubes as a strategic focus for innovation and development. They have remained a priority across three consecutive national Five-Year Plans, underscoring strong government support for advancing homegrown CT tube manufacturing. At the same time, centralized procurement of medical devices is expanding across the country, with the trend gaining momentum. While global giants like GE Healthcare, Siemens Healthcare, and Philips still dominate the mid- to high-end market, they are increasingly facing pressure from rising domestic competitors. Backed by supportive policies and the growing strength of local technologies, the market share of domestically produced CT core components is expected to see steady and sustained growth. 03. 2025 Medtec: Discover Trends, Connect Resources, Unlock Opportunities Breakthroughs in independent innovation are not only transforming the domestic landscape but also offering fresh perspectives and solutions to the global medical technology community. The rapid advancement of localized CT core components marks a major milestone in the evolution of China's medical device industry. 2025 Medtec – the International Exhibition for Medical Device Design & Manufacturing Technology – will serve as a dynamic platform for technical exchange and business collaboration, further accelerating the localization and commercialization of CT core technologies. From domestically developed medical chips to automated precision components, and from non-invasive brain-computer interfaces to nanoscale surgical robots, 2025 Medtec will showcase a full spectrum of cutting-edge medical technologies from around the world. The event offers professionals a unique opportunity to engage in in-depth technical exchanges and gain insights that span from theoretical innovation to real-world industrial applications. Additionally, 2025 Medtec will host an enhanced Medtec International Medical Device Supply Chain Ecosystem Summit, centered on eight key themes: high-end active medical devices, manufacturing processes, innovative material applications, R&D consulting, medical regulations, consumer healthcare, market and procurement, and support services. This summit will foster collaboration and innovation throughout the supply chain. Attendees will have the chance to hear the latest industry insights, engage in direct discussions with experts, and explore new opportunities and challenges shaping the future of the medical device industry. We invite industry professionals from around the world to register and attend this exhibition—come witness the rapid rise of China's CT core component industry and see firsthand how the "heart" of China's high-end medical equipment is beating stronger than ever, showcasing Chinese innovation and strength on the global medical device stage!
Korea Herald
7 hours ago
- Korea Herald
Informa Markets to Host Vitafoods Asia 2025 Fueling the Growth of Asia's Nutraceutical Industry
BANGKOK, Aug. 4, 2025 /PRNewswire/ -- Informa Markets will host Vitafoods Asia 2025 from 17–19 September 2025 at Queen Sirikit National Convention Center (QSNCC) in Bangkok. The event will play a key role in advancing Thailand's food and nutraceutical industries, aligning with the region's growing shift toward preventive healthcare and wellness. According to Market Minds Advisory, the Asia-Pacific nutraceutical market is projected to reach USD 176.5 billion by 2034, growing at a CAGR of 8%. "The rapid growth of the food supplements and nutraceutical sector is fueled by rising consumer health awareness, especially around non-communicable diseases like diabetes, obesity, and cardiovascular conditions," said Ms. Rungphech Chitanuwat, Regional Portfolio Director – ASEAN at Informa Markets. Asia's consumers are increasingly seeking solutions for immunity, weight control, and holistic health. Functional beverages, such as protein and probiotic drinks, are gaining traction—especially among younger demographics. Industry players are focusing on R&D for new technologies and natural ingredients like turmeric, green tea, and herbs. Meanwhile, digital platforms and e-commerce are broadening market reach and offering personalized experiences. "This shift toward preventive healthcare is driving strong demand for functional foods and supplements, paving the way for growth across health food, supplement, and nutritional technology sectors," added Rungphech. What to expect at Vitafoods Asia 2025 Vitafoods Asia 2025 will be a strategic platform for innovation, networking, and global market access. Featuring over 650 leading brands and welcoming more than 13,000 visitors from 38 countries, the event will connect the entire supply chain—from raw ingredients to OEM/ODM services and finished products. Key highlights include: Voices of Supporters and Exhibitors Prof. (Research) Dr. Chutima Eamchotchawalit, President of the Program Management Unit for Competitiveness (PMUC), emphasized the importance of adding value to food supplements through research on Thai ingredients. The agency is compiling a positive list of approved functional ingredients, supporting product development aligned with international standards. "This list will enhance product credibility, ensure consumer safety, and position Thai supplements for global competitiveness," said Dr. Chutima. Mr. Nakah Thawichawatt, Chairman of the Food Supplement Industry Group, Federation of Thai Industries, reaffirmed the sector's potential and the FTI's commitment to elevating industry standards and consumer confidence. Dr. Pat Ekpanyaskun, CEO of Nutrition SC Public Company Limited, praised Vitafoods Asia as a key opportunity to raise brand visibility, build networks, and scale across domestic and global markets. Ms. Jeannie Kwa, Senior HCP Marketing Manager, APAC, from Kaneka Corporation, added that health ageing and longevity are among the fastest-growing categories. Ingredients like NAD+, senolytics, Omega-3, Vitamin D, and collagen are leading product innovation. Pre-registration is now open Vitafoods Asia 2025 will take place from 17–19 September 2025, Level LG, QSNCC, Bangkok. You can secure the privileges by pre-registering to attend at About Informa Markets Vitafoods is organised by Informa Markets, a division of Informa plc. Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Its portfolio comprises more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. Informa Markets provides customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world's leading exhibitions organiser, the company brings a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive, 365 days of the year. For more information, please visit
Korea Herald
3 days ago
- Korea Herald
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31 st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that outlines shared priorities, strategies, and recommendations to elevate the standard of lung cancer care across diverse health systems. Held on the eve of World Lung Cancer Day, the initiative involved over 43 contributors, including clinicians, academics, patient advocates, and health organisations across 14 APAC health systems. Launch Highlights and Key Voices The APAC Lung Cancer Policy Consensus was launched with keynote contributions from: Lung cancer remains the leading cause of cancer-related deaths in the APAC region, and accounts for nearly 60% of global cases. With regional incidence projected to exceed 1.8 million by 2040, the need for a cohesive, regional strategy to combat the disease has never been more urgent. Furthermore, survival rates in the APAC region often lag behind global benchmarks, with five-year survival rates frequently below 20%. This fragmented landscape highlights the critical need for a coordinated approach, one that addresses the unique epidemiological, environmental, and healthcare challenges within the region. The APAC Lung Cancer Policy Consensus is the result of an extensive collaborative process involving two expert working sessions, one patient workshop and a final expert voting session, with input from patients, clinicians and academic leaders across the region. The consensus lays out a unified policy framework anchored in five core principles, all aimed at driving sustainable, equitable improvements in lung cancer prevention, detection, treatment, and stigma reduction across the region. Importantly, the APAC Consensus aligns closely with the Global Lung Cancer Consensus, which was first ratified at the 9th International Lung Cancer Network in 2023. By endorsing this global statement, the APAC region reaffirms its commitment to improving lung cancer outcomes. The Five Global Principles Anchoring the : A Region-Specific Approach to Lung Cancer Care The APAC Lung Cancer Policy Consensus is not just a regional adaptation of global recommendations; it is a comprehensive response to the distinct challenges faced by the APAC region. Unlike Western health systems that primarily focus on smoking-related lung cancer, the APAC region must contend with a higher prevalence of lung cancer in never-smokers due to factors such as environmental pollutants, and genetic predispositions. Moreover, the region's healthcare systems are highly heterogeneous, ranging from well-resourced settings with cutting-edge cancer care to lower-resource environments building on basic cancer services. Given these disparities, a one-size-fits-all approach would be ineffective. The APAC Lung Cancer Policy Consensus presents a regionally tailored action plan that offers specific strategies and targets to improve lung cancer care and outcomes, ensuring that every health system in the region, regardless of its capacity, can make progress toward the shared goals. "We call on policymakers, healthcare leaders, and stakeholders across the APAC region to urgently prioritise and implement policies that improve lung cancer outcomes. While the specific solutions will vary across health systems, this consensus provides a shared foundation to guide national efforts. By acting now and adapting these recommendations to local contexts, we can foster a future where healthcare systems of all sizes work together to overcome regional challenges." said Judy Li, Consortium Manager at ASPIRE for Lung Cancer. Looking Ahead The launch of the APAC Lung Cancer Policy Consensus marks the start of a sustained regional effort to transform lung cancer care in the Asia-Pacific region. Over the coming months, ASPIRE for Lung Cancer and its partners will continue to engage with policymakers, healthcare leaders, and patient advocacy groups to ensure that the consensus principles are translated into concrete action, with measurable outcomes. Through this regional collaboration, APAC aims to drive meaningful change that will improve survival rates and quality of life for lung cancer patients across the region. For more details about the APAC Lung Cancer Policy Consensus or to learn how you can get involved in advancing lung cancer care in your region, visit About ASPIRE for Lung Cancer ASPIRE (Asia Pacific Policy Review and Engagement) for Lung Cancer is a collaborative multilateral effort focused on improving lung cancer outcomes in the Asia-Pacific region through policy reforms. We advocate for prioritising lung cancer in government action plans, aiming to drive transformative changes that enhance patient access and care. We believe in the influence of collaboration and collective action to drive positive change. We therefore work with governments, agencies, NGOs and patient groups, bringing together multi-disciplinary experts to improve health outcomes for lung cancer patients in the APAC region.
